They went from dai­ly to once every two months. But how much longer act­ing can HIV meds be? Vi­iV en­lists Halozyme's tech to find out

It wasn’t easy nav­i­gat­ing the man­u­fac­tur­ing and con­trols is­sues that had led the FDA to re­ject Vi­iV Health­care’s first pitch for the once-month­ly HIV reg­i­men cabote­gravir and rilpivirine. But even as Kim­ber­ly Smith was knee-deep in sort­ing out those prob­lems and putting to­geth­er a new pack­age that fi­nal­ly won the reg­u­la­tors over this Jan­u­ary, her busi­ness de­vel­op­ment team kept look­ing for things that would take them to the next lev­el.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER